DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae Curriculum Vitae PERSONAL INFORMATION Carmelo Rizzari WORK EXPERIENCE June 1999- Present Head of the Pediatric Hematology-Oncology Unit University of Milano Bicocca, Hospital S. Gerardo of Monza (Italy) Pediatric Hematology Oncology June 2002-June 2009 Staff Associate Member - High Specialization University of Milano Bicocca, Hospital S. Gerardo of Monza (Italy) Pediatric Hematology Oncology October 1990-June 2002 Staff Assistant Member University of Milano Bicocca, Hospital S. Gerardo of Monza (Italy) Pediatric Hematology-Oncology March 1989-October 1990 Pediatrician Cinisello Balsamo, Milano (Italy) Pediatrics July 1988-September 1988 Medical Service in the public area of care continuity Italian Health Service (Italy) Pediatrics January 1988-May 1988 Medical activity of substitution for General Practitioners or Pediatricians Italian Health Service (Italy) Internal and Emergency Medicine May 1986-September 1988 Permanent Member of the 23rd Commission (ASL Catania) for the evaluation of Civil Invalidity ASL Catania (Italy) Legal medicine and Forensic Sciensces April 1984-October 1985 Medical Officer Italian Military Navy (Italy) Military and Emergency Medicine EDUCATION AND TRAINING November 1977-July 1983 Degree in Medicine and Surgery (Mentor: Prof. G. Russo, Catania) 110/110 cum laude Univerisyt of Catania, School of Medicine and Surgery (Italy) Medicine and Surgery July 1983-November 1983 National abilitation to professional medical activities University of Catania, School of Medicine (Italy) Medicine and Surgery July 1984-August 1984 Stage in pediatric hematology-oncology, Department of Pediatrics, Pediatric 15/12/2020 European Medicine Agency Page 1/17 hematology- Oncology Unit (Mentors: Prof. Martii Siimes, Prof. Mikko Perkkio) University of Helsinki University of Helsinki (Finland) Pediatric Hematology-Oncology February 1985-December 1985 Employment as staff assistant member while resident in Pediatrics at the Department of Pediatrics University of Catania (Italy) Pediatric Hematology-Oncology January 1987-September 1988 Stage in pediatric hematology-oncology, Department of Pediatrics, University of Milano, Hospital S. Gerardo of Monza (Mentor: Prof. Giuseppe Masera) . University of Milano Bicocca, Hospital S. Gerardo of Monza (Italy) Pediatric Hematology-Oncology November 1984-July 1988 Specialization in Pediatrics (Mentor: Prof. G. Schilirò) 50/50 cum laude (Italy) Pediatric Hematology-Oncology April 1997-October 1997 Visiting Scientist, Department of Clinical Pharmacology, St. Jude Childrens Research Hospital (Mentors: Dr. Mary V. Relling, Dr. William E. Evans), Memphis, TN, USA University of Tennessee, Memphis (United States) Pediatric Hematology-Oncology, Clinical Pharmacology ADDITIONAL INFORMATION Expertise Involved since the late 80ies in the field of pediatric leukemias with special expertise developed in the field of cancer chemotherapy. Currently he is the full Responsible of the Pediatric Hematology-Oncology Unit in Monza, which is the largest and first recruiting center for hematological malignancies in Italy. His main professional and scientific achievements are listed below: Participation in the development and drafting of the chemotherapy protocols adopted in Italy since the late 80ies by the AIEOP for the first-line (AIEOP LLA 91, 95, 2000) and second line (REC 98, REC 98, INTREALL) treatment of Acute Lymphoblastic Leukemia. Participation in the development and drafting of the chemotherapy protocols adopted in Italy since the late 90ies by the AIEOP for the first-line (AML AIEOP 2002/01-02) and second line (IBFMSG Relapsed AML 2002 study) treatment of Acute Myeloid Leukemia. Member of the Trial Steering Committee of the currently ongoing international AIEOP-BFM ALL 2009 Study and coordinator for the pharmacological studies conducted in this trial for E.Coli PEG-ASP and Erwinia C. ASP. Major efforts have been aimed at a better management and understanding on this drug. Member of the AIEOP Trial Steering Committee for the AIEOP ALL and AML front-line and relapsed trials. He is also a member of the AIEOP committee for Myelodisplastic Syndromes. Co-cordinator since 2007 of the national protocol AIEOP ALL REC 2003 for relapsed acute lymphoblastic leukemia. Co-Principal Investigator for Italy in the European protocol IntReALL 2010 funded under the FP7 project for the European Community. In the frame of this trial he has been appointed coordinator of the european working group on studies for ASP. Principal investigator of the Italian international randomized studies AML 2001/01 (FLAG ± DaunoXome) of the International BFM Study Group. Member of the Trial Steering Committe for the upcoming european study for Relapsed AML I-BFM-SG AML Relapsed 2014. Member of the European Working Group for the design and implementation of a common european 15/12/2020 European Medicine Agency Page 2/17 protocol to be started in 2017-2018. Coordinator of the Working Group for surveillance studies of complications and toxic events in AIEOP protocols for acute lymphoblastic leukemia. Italian Principal Investigator and member of the 'European Advisory Board of the international randomized EPO-INT-51 on the role of erythropoietin Alfa in the treatment of pediatric patients with acute lymphoblastic leukemia or solid tumors. Local Principal Investigator of several Phase I-II studies on Clofarabine (Amgen), Dasatinib (Bristol Myers Squibb) Forodesine (Mundipharma), Midostaurine (Novartis), Nilotinib (Novartis), Blinatumomab (Amgen), Bortezomib (Academic Trial), NI-0501-04 (Novimmune), Volasertib (Boehringer Ingelheim), Azacytidine (Celgene). Currently he is the local PI of several additional studies with innovative drugs or strategies. "Expert Consultant" independent outside of the "Therapeutic Expert Group "for the part relating to leukemias and lymphomas" within the project called "TEDDY" (acronym for Task-force in Europe for Drug Development for the Young) Since June 2010 member on behalf of the Italian centers, of the International Quality and Accreditation Committee of the european ITCC (Innovative Therapies in Children with Cancer) consortium. Since May 2012 coordinator of the AIEOP working group for Clinical Pharmacology and Pharmacovigilance. In 2013 enabled to hold the position of associate professor in the national academic selection for the General and Specialistic areas of Pediatrics (MED38). Author and coauthor of 80 publications (see attached list) in relevant, high IF scored, peer reviewed journals (Lancet, JCO, Blood, BJH, BJC, Cancer, Haematologica, Leukemia) and author of the follwinfg chapters in scientific books: Asparaginase Treatment on Treatment of acute leukemias new directions for clinical research, edited by CH Pui, Humana Press, New Jersey, 2002. Le leucemie acute in età pediatrica in Fondamenti di Oncologia Clinica, Editors. F. Cavalli, F. Cognetti A. Costa, R. Orecchia, Elsevier Italia, 2005 Chairman and speaker at several international scientific conferences and meetings (AIEOP, ASH, SIOP, IBFMSG). Data Monitoring Committee Member or Chairman for phase I-II pediatric clinical trials regarding anticancer agents and supportive therapy drugs in the field of pediatric hematology and oncology. Lecturer for students of the Medical School and for post-graduates and residents of the School of Specialization in Paediatrics Tutor, supervisor and co-rapporteur of several theses of the Medical School and of the Residency School in Pediatrics of the University of Milano Bicocca. Peer-reviewer for several scientific journals in the field of Hematology-Oncology (Haematologica, Cancer, Pediatric Blood and Cancer, Journal of Pediatric Hematology Oncology, International Journal of Pediatric Hematology and Oncology, Blood, Leukemia, Lancet Oncology, Lancet Haematology).From June 2020 holds the position of full Professor in Pediatrics at the University of Milano Biccoca, MIlano, Italy Frmo 31.12.2019 is the President Elect of the European Society of Pediatric Oncology. Publications Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Von Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C. Pre- existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. 2020 Dec 10;Online ahead of print:0. doi: 10.3324/haematol.2020.258525. PMID: 33299233 D'Angiò M, Fazio G, Grioni A, Palamini S, Sala S, Galbiati M, Biondi A, Balduzzi A, Rizzari C, Cazzaniga G. High Expression due to <i>NRIP1/EVI1</i> Fusion in Therapy-related Acute Myeloid Leukemia: Description 15/12/2020 European Medicine Agency Page 3/17 of the First Pediatric Case. Hemasphere. 2020 Sep 17;4(5):e471. doi: 10.1097/HS9.0000000000000471. PMID: 33163906; PMCID: PMC7643912. Rubio-San-Simón A, André N, Cefalo MG, Aerts I, Castañeda A, Benezech S, Makin G, van Eijkelenburg N, Nysom K, Marshall L, Gambart M, Hladun R, Rossig C, Bergamaschi L, Fagioli F, Carpenter B, Ducassou S, Owens C, Øra I, Ribelles AJ, De Wilde B, Guerra-García P, Strullu M, Rizzari C, Ek T, Hettmer S, Gerber NU, Rawlings C, Diezi M, Palmu S, Ruggiero A, Verdú J, de Rojas T, Vassal G, Geoerger B, Moreno L, Bautista F. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. Eur J Cancer. 2020 Dec;141:82-91. doi: 10.1016/j.ejca.2020.09.024. Epub 2020
Load more

Recommended publications
  • Williams Syndrome Specialized Health Needs Interagency Collaboration
    SHNIC Factsheet: Williams Syndrome Specialized Health Needs Interagency Collaboration What is it? Williams syndrome (WS) is a random genetic mutation disorder that presents at birth, affecting both boys and girls equally. WS is caused by the deletion of genetic material from a specific region of chromosome 7. This disease is characterized by an array of medical problems that can range in severity and age of onset. However, all cases are characterized by dysmorphic facial features, cardiovascular disease, and developmental delay. These disabilities occur in conjunction with striking verbal abilities, highly social personalities, and an affinity for music. What are characteristics? Heart and blood vessel problems Low muscle tone and joint laxity Reflux Dental abnormalities Hypercalcemia Developmental Delays Hearing sensitivity Characteristic facial features: Kidney problems small upturned nose Hernias wide mouth Facial characteristics full lips Chronic ear infection small chin puffiness around the eyes Suggested school accommodations Most children with Williams Syndrome have some form of learning difficulties but they can significant- ly vary. As they age, you may notice the child struggling with concepts like spatial relations, numbers and abstract reasoning. Many children with WS appear scattered in their level of abilities across do- mains. Although a child with WS may be very social, remember to monitor their support systems and social interactions as they often have a difficult time understanding social cues. Physical/Medical
    [Show full text]
  • Williams Syndrome (WS): Recent Research on Music and Sound
    American Music Therapy Association 8455 Colesville Rd., Ste. 1000 • Silver Spring, Maryland 20910 Tel. (301) 589-3300 • Fax (301) 589-5175 • www.musictherapy.org Williams Syndrome (WS): Recent Research on Music and Sound STATEMENT OF PURPOSE Description: Music Therapy (MT) is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Although WS is a rare disease, MTs may have more contact with these clients since many people with WS have a strong affinity for music, melody and song. Parents of children with WS express a strong interest in adaptive music programs for their children. The aim of therapy is to help people with WS to optimize their talents and musical affinity in order to address multiple potential outcomes. MT sessions may include the use of active music making, singing, interactive music play, and improvisational techniques. MT may include both individual and group therapy. STANDARDIZATION: MT sessions are documented in a treatment plan and delivered in accordance with standards of practice. Music selections and certain active music making activities are modified for client preferences and individualized needs (i.e., song selection, musical instruments, and music may vary). REPLICATION: Yes; MT and music special education has been used with different settings, providers, and populations. Research replication in the area of music response and WS is growing. OUTCOMES: Improved global state, enhanced learning, general functioning, improved social functioning, and enhanced leisure time. OVERVIEW OF RESEARCH The prevalence rate for WS is estimated at 0.01% or about 36,266 people in the United States.
    [Show full text]
  • Preimplantation Genetic Screening and Diagnosis
    Lab Management Guidelines v2.0.2019 Preimplantation Genetic Screening and Diagnosis MOL.CU.119.P v2.0.2019 Description Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS) are used to detect genetic conditions, chromosome abnormalities, and fetal sex during assisted reproduction with in vitro fertilization (IVF). PGD refers to embryo testing that is performed when one or both parents have a known genetic abnormality. This includes single-gene mutations and chromosome rearrangements. PGS refers to screening an embryo for aneuploidy when both parents are chromosomally normal. Genetic testing is performed on cells from the developing embryo prior to implantation. Only those embryos not affected with a genetic condition are implanted. PGD may allow at-risk couples to avoid a pregnancy affected with a genetic condition. The Society for Assisted Reproductive Technology and the American Society for Reproductive Medicine have published joint practice committee opinions to address the safety, accuracy, and overall efficacy of PGD and PGS.1,2 This guideline does not include prenatal or preconception carrier screening. Please refer to Genetic Testing for Carrier Status for that purpose. This guideline does not include prenatal genetic testing. Please see Genetic Testing for Prenatal Screening and Diagnostic Testing for genetic testing done during pregnancy. Criteria Criteria: General coverage guidance Preimplantation genetic diagnosis may be considered when ALL of the following conditions are met: Technical and clinical validity: The test must be accurate, sensitive and specific, based on sufficient, quality scientific evidence to support the claims of the test. In the case of PGD, the mutation(s) or translocation(s) to be tested in the embryo should first be well-characterized in the parent(s) AND the embryonic test results must be demonstrated to be highly accurate.
    [Show full text]
  • The Behavioural Phenotype of Angelman Syndrome
    The behavioural phenotype of Angelman syndrome. Horsler, K. and Oliver, C. Cerebra Centre for Neurodevelopmental Disorders, School of Psychology, University of Birmingham Please use this reference when citing this work: Horsler, K. and Oliver, C. (2006). The behavioural phenotype of Angelman syndrome. Journal of Intellectual Disability Research , 50 , 33-53. The Cerebra Centre for Neurodevelopmental Disorders, School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT Website: www.cndd.Bham.ac.uk E-mail : [email protected] 1 ABSTRACT Background. The purpose of this review is to examine the notion of a behavioural phenotype for Angelman syndrome and identify methodological and conceptual influences on the accepted presentation. Method. Studies examining the behavioural characteristics associated with Angelman syndrome are reviewed and methodology is described. Results. Potential bias in the description of the phenotype emerges with the use of case and cohort studies with the absence of comparison groups. A trend in the literature from a direct gene effect to a socially mediated effect on laughter is evident. Conclusion. Evidence for a behavioural phenotype of Angelman syndrome has begun to emerge. However, by adopting the concept of a ‘behavioural phenotype’, attention may become biased towards the underlying biological basis of the syndrome, with developmental and environmental factors being overlooked. 2 INTRODUCTION Angelman described three children in 1965 who all presented with intellectual disability
    [Show full text]
  • 7Q Deletions Proximal Interstitial FTNW
    7q deletions proximal interstitial rarechromo.org A 7q deletion A 7q deletion is a chromosome disorder . A chromosome disorder is a change in chromosome number or structure which results in a set of features or symptoms. People with a 7q deletion have lost a small but variable amount of genetic material from one of their 46 chromosomes. Chromosomes and genes Chromosomes are made up of DNA and are the structure in the nucleus of the body’s cells that carry genetic information (known as genes), telling the body how to develop and function. They come in 23 pairs, one from each parent. Twenty-two of the pairs are numbered 1- 22 according to size, from the largest to the smallest. In addition to these 44 chromosomes, each person has another pair of chromosomes, called the sex chromosomes. Girls have two Xs (XX), whereas boys have an X and a Y chromosome (XY). Each chromosome has a short (p) arm (at the top in the diagram on the next page) and a long (q) arm (the bottom part of the chromosome). For healthy development, chromosomes should contain just the right amount of material – not too much and not too little. People with a 7q deletion have one intact chromosome 7, but the other chromosome is missing a piece. This means that there is only one copy instead of the usual two of a number of genes. As chromosome 7 is a medium-sized chromosome, the genes on it represent about 4-6 per cent of the total number of genes in the human genome.
    [Show full text]
  • The Fragile X Syndrome–Autism Comorbidity: What Do We Really Know?
    REVIEW ARTICLE published: 16 October 2014 doi: 10.3389/fgene.2014.00355 The fragile X syndrome–autism comorbidity: what do we really know? Leonard Abbeduto 1,2*, Andrea McDuffie 1,2 and Angela John Thurman 1,2 1 MIND Institute, University of California, Davis, Sacramento, CA, USA 2 Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento, CA, USA Edited by: Autism spectrum disorder (ASD) is a common comorbid condition in people with fragile Anne C. Wheeler, Carolina Institute X syndrome (FXS). It has been assumed that ASD symptoms reflect the same underlying for Developmental Disabilities; University of North Carolina at psychological and neurobiological impairments in both FXS and non-syndromic ASD, which Chapel Hill, USA has led to the claim that targeted pharmaceutical treatments that are efficacious for core Reviewed by: symptoms of FXS are likely to be beneficial for non-syndromic ASD as well. In contrast, we Molly Losh, Northwestern present evidence from a variety of sources suggesting that there are important differences University, USA in ASD symptoms, behavioral and psychiatric correlates, and developmental trajectories Dejan Budimirovic, Kennedy Krieger Institute/The Johns Hopkins between individuals with comorbid FXS and ASD and those with non-syndromic ASD. We University, USA also present evidence suggesting that social impairments may not distinguish individuals *Correspondence: with FXS with and without ASD. Finally, we present data that demonstrate that the Leonard Abbeduto, MIND Institute, neurobiological substrates of the behavioral impairments, including those reflecting core University of California, Davis, 2825 ASD symptoms, are different in FXS and non-syndromic ASD. Together, these data suggest 50th Street, Sacramento, CA 95817, USA that there are clinically important differences between FXS and non-syndromic ASD e-mail: leonard.abbeduto@ucdmc.
    [Show full text]
  • A Comparison of Down Syndrome and Williams Syndrome
    ndrom Sy es tic & e G n e e n G e f T o Vicari et al., J Genet Syndr Gene Ther 2016, 7:1 Journal of Genetic Syndromes h l e a r n a DOI: 10.4172/2157-7412.1000279 r p u y o J & Gene Therapy ISSN: 2157-7412 Research Article Open Access Detecting Psychiatric Profile in Genetic Syndromes: A Comparison of Down Syndrome and Williams Syndrome Stefano Vicari1*, Floriana Costanzo1, Marco Armando1, Giovanni Carbonara1, Pamela Varvara1, Cristina Caciolo1, Chiara Gagliardi2, Tiziana Gianesini3, Paolo Alfieri1, Rossella Capolino1 and Deny Menghini1 1Bambino Gesù Children’s Hospital, Rome, Neuroscience Department, Italy 2Eugenio Medea Institute, Neurorehabilitation Unit, Bosisio Parini, Lecco 3AGBD Down Syndrome Association, Physical Medicine and Rehabilitation Clinic, Marzana, Verona Abstract The occurrence and co-occurrence of psychiatric disorders have been more frequently reported in people with Intellectual Disability (ID) than in the general population. The present study was aimed at verifying whether the psychiatric profile of individuals with ID is just a consequence of ID or derives from a specific genotype. The psychiatric profile of 112 individuals with Down syndrome (DS) and 85 with Williams syndrome (WS) was examined. The interactions between psychiatric symptom clusters and the effect of age were also investigated. Participants with WS had higher rates of psychiatric disorders, and, specifically, of Anxiety disorders and Psychosis than DS. However, the psychiatric profile changed by age, since Anxiety disorder was higher in individuals with WS compared to DS in young age, while Psychosis in old age. A relation between the occurrence of disorders, as Anxiety disorder and Mood Disorder, was found only in participants with WS.
    [Show full text]
  • Determining the Genetic Contributions of the Williams Syndrome Critical Region to Behavior Using Mouse Models and Human Genetics
    Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Summer 8-15-2019 Determining the Genetic Contributions of the Williams Syndrome Critical Region to Behavior Using Mouse Models and Human Genetics Nathan David Kopp Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Genetics Commons, and the Neuroscience and Neurobiology Commons Recommended Citation Kopp, Nathan David, "Determining the Genetic Contributions of the Williams Syndrome Critical Region to Behavior Using Mouse Models and Human Genetics" (2019). Arts & Sciences Electronic Theses and Dissertations. 1779. https://openscholarship.wustl.edu/art_sci_etds/1779 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Human and Statistical Genetics Dissertation Examination Committee: Joseph Dougherty, Chair Yehuda Ben-Shahar Don Conrad Harrison Gabel Christina Gurnett Beth Kozel Determining the Genetic Contributions of the Williams Syndrome Critical Region to Behavior Using Mouse Models and Human Genetics by Nathan Kopp A dissertation presented to
    [Show full text]
  • Neurological Syndromes
    Neurological Syndromes J. Gordon Millichap Neurological Syndromes A Clinical Guide to Symptoms and Diagnosis J. Gordon Millichap, MD., FRCP Professor Emeritus of Pediatrics and Neurology Northwestern University Feinberg School of Medicine Chicago, IL, USA Pediatric Neurologist Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago , IL , USA ISBN 978-1-4614-7785-3 ISBN 978-1-4614-7786-0 (eBook) DOI 10.1007/978-1-4614-7786-0 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013943276 © Springer Science+Business Media New York 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • What Is 22Q11.2 Deletion Syndrome? 22Q11.2 Deletion Syndrome Is a Genetic Condition That Affects Learning, Health, and Physical Traits
    What is 22q11.2 Deletion Syndrome? 22q11.2 deletion syndrome is a genetic condition that affects learning, health, and physical traits. It occurs in males and females of all racial and ethnic backgrounds. 22q11.2 deletion syndrome occurs in about 1 in 4,000 to 6,000 people. It is sometimes known as Velocardiofacial or DiGeorge syndrome. How may the syndrome affect my child? Michigan Resources & Support Learning: There is a range of abilities. often noticed only by a medical Some children with 22q11.2 deletion professional. Short stature is also a Children’s Special Health Care may have normal learning, while others common trait. Services Family Phone Line have a developmental delay, learning Toll-free: 1-800-359-3722 disability or severe lifelong learning Medical: Heart defects are very E-mail: [email protected] problems. common. They can be mild or severe www.michigan.gov/cshcs enough to need surgery. Many Behavior: Mental (psychiatric) children have palate abnormalities. Early On® Michigan illnesses including depression, bipolar These include an opening in the roof Toll-free: 1-800-EARLY ON disorder and schizophrenia have been of the mouth (cleft palate) and a www.1800earlyon.org reported in some people with 22q11.2 change in the way the throat closes deletion syndrome. (velopharyngeal incompetence). Michigan Birth Defects Program Other medical problems can include Nurse Follow-up Coordinator Physical: Children with 22q11.2 kidney abnormalities, problems with Toll-free: 1-866-852-1247 deletion syndrome may have certain the immune system and low calcium E-mail: [email protected] facial features, such as a prominent levels.
    [Show full text]
  • Hashimoto's Thyroiditis and Graves' Disease in Genetic Syndromes In
    G C A T T A C G G C A T genes Review Hashimoto’s Thyroiditis and Graves’ Disease in Genetic Syndromes in Pediatric Age Celeste Casto, Giorgia Pepe , Alessandra Li Pomi, Domenico Corica , Tommaso Aversa and Malgorzata Wasniewska * Department of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, 98124 Messina, Italy; [email protected] (C.C.); [email protected] (G.P.); [email protected] (A.L.P.); [email protected] (D.C.); [email protected] (T.A.) * Correspondence: [email protected]; Tel.: +39-328-6522425 Abstract: Autoimmune thyroid diseases (AITDs), including Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), are the most common cause of acquired thyroid disorder during childhood and adolescence. Our purpose was to assess the main features of AITDs when they occur in association with genetic syndromes. We conducted a systematic review of the literature, covering the last 20 years, through MEDLINE via PubMed and EMBASE databases, in order to identify studies focused on the relation between AITDs and genetic syndromes in children and adolescents. From the 1654 references initially identified, 90 articles were selected for our final evaluation. Turner syndrome, Down syndrome, Klinefelter syndrome, neurofibromatosis type 1, Noonan syndrome, 22q11.2 deletion syndrome, Prader–Willi syndrome, Williams syndrome and 18q deletion syndrome were evaluated. Our analysis confirmed that AITDs show peculiar phenotypic patterns when they occur in association with some genetic disorders, especially chromosomopathies. To improve clinical practice and healthcare in children and adolescents with genetic syndromes, an accurate screening and monitoring of thyroid function and autoimmunity should be performed.
    [Show full text]
  • Quantifying the Resolution of Spatial and Temporal Representation in Children with 22Q11.2 Deletion Syndrome Kathryn L
    McCabe et al. Journal of Neurodevelopmental Disorders (2019) 11:40 https://doi.org/10.1186/s11689-019-9301-1 RESEARCH Open Access Quantifying the resolution of spatial and temporal representation in children with 22q11.2 deletion syndrome Kathryn L. McCabe1,2* , Abbie M. Popa1, Courtney Durdle1, Michele Amato1, Margarita H. Cabaral1, Joshua Cruz1, Ling M. Wong1,2, Danielle Harvey3, Nicole Tartaglia4 and Tony J. Simon1,2 Abstract Objectives: Our ability to generate mental representation of magnitude from sensory information affects how we perceive and experience the world. Reduced resolution of the mental representations formed from sensory inputs may generate impairment in the proximal and distal information processes that utilize these representations. Impairment of spatial and temporal information processing likely underpins the non-verbal cognitive impairments observed in 22q11.2 deletion syndrome (22q11DS). The present study builds on prior research by seeking to quantify the resolution of spatial and temporal representation in children with 22q11DS, sex chromosome aneuploidy (SCA), and a typically developing (TD) control group. Participants and methods: Children (22q11DS = 70, SCA = 49, TD = 46) responded to visual or auditory stimuli with varying difference ratios. The participant’s task was to identify which of two sequentially presented stimuli was of larger magnitude in terms of, size, duration, or auditory frequency. Detection threshold was calculated as the minimum difference ratio between the “standard” and the “target” stimuli required to achieve 75% accuracy in detecting that the two stimuli were different. Results: Children with 22q11DS required larger magnitude difference between spatial stimuli for accurate identification compared with both the SCA and TD groups (% difference from standard: 22q11DS = 14; SCA = 8; TD: 7; F = 8.42, p < 0.001).
    [Show full text]